Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study | Synapse
Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
Key Points
Topical GT20029 demonstrated significant efficacy in hair regrowth with good tolerability, enhancing treatment options.
A double-blind, placebo-controlled phase 2 study evaluated the effects of topical GT20029 in male patients.
The multicenter design allows for diverse patient recruitment, increasing generalizability of results.
Further studies are warranted to confirm its therapeutic potential in androgenetic alopecia.
Abstract
Topical GT20029 demonstrated significant efficacy in hair regrowth with good tolerability. Further studies are warranted to confirm its therapeutic potential in AGA.